🔔Stock Alerts via Telegram — Free for All Users

PRGO Stock Risk & Deep Value Analysis

Perrigo Company PLC

DVR Score

2.2

out of 10

Risk Trap

What You Need to Know About PRGO Stock

We analyzed Perrigo Company PLC using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran PRGO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Apr 18, 2026Run Fresh Analysis →

PRGO Risk Analysis & Red Flags

What Could Go Wrong

Perrigo's ongoing negative net margins and declining revenue could persist if cost-cutting measures are insufficient to offset macro pressures and intense competition. This could lead to further multiple contraction, pressure on the dividend, and difficulty in executing its deleveraging strategy, ultimately diminishing shareholder value.

Risk Matrix

Overall

Aggressive

Financial

Medium

Market

High

Competitive

High

Execution

Medium

Regulatory

Low

Red Flags

  • Declining revenue (-2.5% YoY in Q4 2025)

  • Deeply negative net margin (-33.51%) reflecting ongoing losses

  • Workforce reduction (~7%) indicating operational distress and cost-cutting focus, not growth

  • Analyst consensus 'Reduce' with 2 'Sell' ratings

  • High dividend yield (10.7%) potentially signaling limited growth opportunities and capital being returned instead of reinvested for growth

Upcoming Risk Events

  • 📅

    Continued soft demand in OTC/infant nutrition segments

  • 📅

    Persistent currency headwinds and inflationary pressures impacting margins

When to Reconsider

  • 🚪

    Exit if quarterly revenue declines accelerate beyond -5% YoY consistently

  • 🚪

    Sell if free cash flow turns consistently negative for two consecutive quarters

  • 🚪

    Re-evaluate position if the quarterly dividend is cut, indicating financial strain

Unlock PRGO Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Perrigo represents a deep value, turnaround play within the consumer self-care sector. The investment thesis relies on management's ability to successfully execute its deleveraging and cost-cutting initiatives, stabilize revenue, return to consistent profitability, and potentially divest non-core assets efficiently. The significant dividend yield offers income while investors await a potential multiple re-rating as the company demonstrates sustained operational improvements, rather than exponential growth.

Is PRGO Stock Undervalued?

Perrigo continues to operate in a mature, highly competitive consumer self-care market, evident from its Q4 2025 revenue decline (-2.5% YoY) and significant net losses (-33.51% net margin). While the company maintains a stable balance sheet with positive free cash flow and a commitment to its dividend, its strategic focus on cost reduction (workforce cuts) and portfolio optimization (infant formula review) are typical of a defensive turnaround, not a high-growth investment. There is no evidence of disruptive innovation, hyper-scalability, or expanding competitive advantages that would support a 10x growth potential within 3-5 years. Analyst sentiment is predominantly negative ('Reduce'), and the median price target offers only modest upside, far short of the required exponential growth.

Unlock the full AI analysis for PRGO

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

PRGO Price Targets & Strategy

12-Month Target

$19.33

Bull Case

$25.00

Bear Case

$8.50

Valuation Basis

Based on analyst median target of $19.33, reflecting a modest recovery to ~7x forward P/E on estimated FY26 EPS of $2.72.

Entry Strategy

Consider dollar-cost averaging on dips towards the $10-$11 range, aligning with recent price action and potential support zones.

Exit Strategy

Take profit at $19-$22. Stop loss below $10.00 if turnaround efforts falter or financial performance deteriorates further.

Portfolio Allocation

1-3% for conservative investors seeking a value turnaround play with dividend income; not suitable for aggressive growth portfolios.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is PRGO Financially Healthy?

Valuation

P/E Ratio

20.90

Forward P/E

21.30

EV/EBITDA

12.50

PEG Ratio

0.85

Price/Book

2.50

Price/Sales

0.90

Profitability

Gross Margin

35.14%

Operating Margin

-26.39%

Net Margin

-33.51%

Return on Equity

-35.16%

Revenue Growth

-2.75%

EPS

$-10.36

Balance Sheet

Current Ratio

2.76

Quick Ratio

1.44

Debt/Equity

1.24

Total Debt

$2.10B

Cash & Equivalents

$1.80B

Cash Flow

Operating Cash Flow

$950.00M

Free Cash Flow

$620.00M

EBITDA

$1.40B

Other

Beta (Volatility)

0.53

Dividend Yield

10.16%

Does PRGO Have a Competitive Moat?

Sign in to unlock

Moat Rating

🛡️ Narrow

Moat Trend

Stable

Moat Sources

3 Identified

Brand PowerCost Advantages (from scale and efficiency in private label/generics)Intangible Assets/IP (limited patents, mostly related to specific OTC formulations)

Perrigo's moat derives primarily from its established brands in mature categories and its efficient supply chain for private label products. This provides a stable, but not expanding, competitive barrier against new entrants, but offers limited defense against large, diversified consumer health rivals or disruptive innovation.

Moat Erosion Risks

  • Intense price competition in private label and generic OTC markets
  • Changing consumer preferences or disruptive digital health trends bypassing traditional retail channels

PRGO Competitive Moat Analysis

Sign up to see competitive advantages

PRGO Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral (likely low retail interest given the company's turnaround phase and lack of high-growth narrative)

Institutional Sentiment

Negative (1 Buy, 3 Hold, 2 Sell ratings, consensus 'Reduce'; Canaccord Genuity cut target, Weiss 'Sell')

Insider Activity (Form 4)

EVP & CFO Eduardo Guarita Bezerra exercised 6,369 RSUs into shares on 2026-04-02; EVP & CHRO Robert Willis exercised 2,070 RSUs on 2026-04-02. These are RSU exercises for compensation, not open-market purchases indicating conviction.

Options Flow

Normal options activity (no unusual options flow data was provided in the research)

Earnings Intelligence

Next Earnings

2026-05-06

Surprise Probability

Medium (Zacks revised Q1 2026 EPS estimate down, suggesting caution, but Q4 2025 beat revenue)

Historical Earnings Pattern

Historically, Perrigo's stock has shown mixed reactions to earnings, often influenced more by guidance and progress on strategic initiatives than by minor beats or misses on individual quarterly figures, given its ongoing turnaround.

Key Metrics to Watch

Organic revenue growth (or deceleration of decline)Improvement in net margin and path to profitabilityFree cash flow generation and commentary on debt reductionUpdates on Infant Formula strategic review and workforce reduction benefits

Competitive Position

Top Competitor

No specific competitor identified in research, but general consumer health/OTC players are strong.

Market Share Trend

Stable in core areas but faces intense competition and soft demand in some segments (e.g., infant nutrition). No specific market share gains reported.

Valuation vs Peers

Perrigo trades at a significant discount on P/S (0.35x vs. Pharmaceuticals sector median 4.59x), reflecting its negative net margin and revenue decline. Its negative P/E makes direct comparison difficult but signals deep underperformance.

Competitive Advantages

  • Strong brand recognition in specific OTC categories
  • Established retail partnerships and distribution network
  • Portfolio of essential self-care products with inelastic demand

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive PRGO Stock Higher?

Near-Term (0-6 months)

  • Q1 2026 Earnings report on 2026-05-06
  • Outcome of Infant Formula segment strategic review

Medium-Term (6-18 months)

  • Continued execution on cost-saving initiatives and workforce reduction benefits
  • Potential divestiture of non-core assets to reduce debt and improve focus

Long-Term (18+ months)

  • Strengthening of core self-care brands and market position through innovation
  • Shift in consumer preferences towards specific OTC categories targeted by Perrigo

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for PRGO?

  • Consistent improvement in organic revenue growth (moving from negative to positive)

  • Progress towards achieving positive net income and expanding operating margins

  • Successful conclusion of the Infant Formula strategic review that enhances shareholder value

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

How Perrigo Company PLC Makes Money

Perrigo Company PLC is a global consumer self-care company that develops, manufactures, markets, and distributes a diverse portfolio of over-the-counter (OTC) health and wellness products, as well as infant formula. The company primarily sells its products to retailers and wholesalers, offering both its own branded products and private label (store brand) equivalents. Its business model relies on leveraging strong brand recognition, efficient manufacturing, and extensive distribution networks to capture market share in essential consumer health categories.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Perrigo Company PLC (PRGO)?

As of April 18, 2026, Perrigo Company PLC has a DVR Score of 2.2 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Perrigo Company PLC?

Perrigo Company PLC's market capitalization is approximately $1.6B..

What is the risk level for PRGO stock?

Our analysis rates Perrigo Company PLC's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of PRGO?

Perrigo Company PLC currently has a price-to-earnings (P/E) ratio of 20.9. This is in line with broader market averages.

Does Perrigo Company PLC pay a dividend?

Yes, Perrigo Company PLC pays a dividend with a current yield of approximately 10.16%.

Is Perrigo Company PLC's revenue growing?

Perrigo Company PLC has reported revenue growth of -2.8%. Revenue has been declining, which warrants closer examination.

Is PRGO stock profitable?

Perrigo Company PLC has a profit margin of -33.5%. The company is currently unprofitable.

How often is the PRGO DVR analysis updated?

Our AI-powered analysis of Perrigo Company PLC is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 18, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PRGO (Perrigo Company PLC) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.

Navigated to PRGO Stock Risk & Deep Value Analysis